335 related articles for article (PubMed ID: 38305642)
1. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa.
Younossi ZM; Golabi P; Paik J; Owrangi S; Yilmaz Y; El-Kassas M; Alswat K; Alqahtani SA
Liver Int; 2024 Apr; 44(4):1061-1070. PubMed ID: 38305642
[TBL] [Abstract][Full Text] [Related]
2. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38521116
[TBL] [Abstract][Full Text] [Related]
3. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
Golabi P; Paik JM; AlQahtani S; Younossi Y; Tuncer G; Younossi ZM
J Hepatol; 2021 Oct; 75(4):795-809. PubMed ID: 34081959
[TBL] [Abstract][Full Text] [Related]
4. The Profile of Non-Communicable Disease (NCD) research in the Middle East and North Africa (MENA) region: Analyzing the NCD burden, research outputs and international research collaboration.
Aggarwal A; Patel P; Lewison G; Ekzayez A; Coutts A; Fouad FM; Shamieh O; Giacaman R; Kutluk T; Khalek RA; Lawler M; Boyle P; Sarfati D; Sullivan R
PLoS One; 2020; 15(4):e0232077. PubMed ID: 32339197
[TBL] [Abstract][Full Text] [Related]
5. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
Younossi ZM; Alqahtani SA; Alswat K; Yilmaz Y; Keklikkiran C; Funuyet-Salas J; Romero-Gómez M; Fan JG; Zheng MH; El-Kassas M; Castera L; Liu CJ; Wai-Sun Wong V; Zelber-Sagi S; Allen AM; Lam B; Treeprasertsuk S; Hameed S; Takahashi H; Kawaguchi T; Schattenberg JM; Duseja A; Newsome PN; Francque S; Spearman CW; Castellanos Fernández MI; Burra P; Roberts SK; Chan WK; Arrese M; Silva M; Rinella M; Singal AK; Gordon S; Fuchs M; Alkhouri N; Cusi K; Loomba R; Ranagan J; Eskridge W; Kautz A; Ong JP; Kugelmas M; Eguchi Y; Diago M; Yu ML; Gerber L; Fornaresio L; Nader F; Henry L; Racila A; Golabi P; Stepanova M; Carrieri P; Lazarus JV;
J Hepatol; 2024 Mar; 80(3):419-430. PubMed ID: 37984709
[TBL] [Abstract][Full Text] [Related]
6. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
7. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Targher G; Byrne CD; Tilg H
Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Surveillance in the Middle East and North Africa: Longitudinal Trend Analysis.
Post L; Marogi E; Moss CB; Murphy RL; Ison MG; Achenbach CJ; Resnick D; Singh L; White J; Boctor MJ; Welch SB; Oehmke JF
J Med Internet Res; 2021 Jan; 23(1):e25830. PubMed ID: 33302252
[TBL] [Abstract][Full Text] [Related]
9. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
Hepatol Res; 2024 Jun; 54(6):600-605. PubMed ID: 38234088
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease in Asia, Africa, and Middle East Region.
Ong J; Alswat K; Hamid S; El-Kassas M
Clin Liver Dis; 2023 May; 27(2):287-299. PubMed ID: 37024208
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
[TBL] [Abstract][Full Text] [Related]
12. Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population.
Liu C; Li N; Sheng D; Shao Y; Qiu L; Shen C; Liu Z
Lipids Health Dis; 2024 Apr; 23(1):104. PubMed ID: 38616253
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of type 2 diabetes, prediabetes, and gestational diabetes mellitus in women of childbearing age in Middle East and North Africa, 2000-2017: protocol for two systematic reviews and meta-analyses.
Al-Rifai RH; Aziz F
Syst Rev; 2018 Jul; 7(1):96. PubMed ID: 30021654
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based investigational therapies for the treatment of MASLD/MASH.
Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
[TBL] [Abstract][Full Text] [Related]
16. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
Song R; Li Z; Zhang Y; Tan J; Chen Z
Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
[TBL] [Abstract][Full Text] [Related]
17. Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study.
Taniguchi H; Ueda M; Sano F; Kobayashi Y; Shima T
JGH Open; 2024 May; 8(5):e13082. PubMed ID: 38779132
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological status of type 2 diabetes mellitus in the Middle East and North Africa, 1990-2019.
Moradinazar M; Babakhani M; Rostami R; Shakiba M; Moradi A; Shakiba E
East Mediterr Health J; 2022 Jul; 28(7):478-488. PubMed ID: 35959663
[TBL] [Abstract][Full Text] [Related]
19. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
[TBL] [Abstract][Full Text] [Related]
20. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N; Copur-Dahi N; Loomba R
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
